PFDeNA
ActiveAI-nativeDeveloper of artificial intelligence based cancer detection platform.
What it does
PFDeNA is offering artificial intelligence based cancer detection platform. The platform determines the presence or absence of cancer, based on the amount of gene expression of ExRNA present in blood using deep learning technology. The ExRNA or miRNA (microRNA) contribute to the regulation of various biological activities and are applied as diagnostic biomarkers. It is a joint venture of DeNA and Preferred Networks
Next to it in Healthcare and bio · AI cancer detection via blood biomarkers
- AI Medical ServicePlug and Play
AI Medical Service is a Tokyo-based company developing AI software to help detect gastric cancer.
- AI Medical ServicePlug and Play
AI Medical Service is a Tokyo-based company developing AI software to help detect gastric cancer.
- IcariaPlug and Play
We can capture 99% of urinary exosome using our nanowire device, and we are now working on early detection of cancer by analyzing miRNA profile extracted from urinary exosome.
- LINDA LifetechPlug and Play
LINDA is a platform that helps doctors and healthcare professionals in the early detection of breast cancer
- MILK Co,.LtdPlug and Play
AI Software Developer for Medical Services
- NodexusPlug and Play
Nodexus is democratizing access to live single cells for applications including gene editing, drug development, and more.
- SyantraPlug and Play
Syantra Inc. is a precision healthcare company changing the way cancer is detected and treated, starting with breast cancer.
- X-ZellY Combinator W15
Early, pain-free cancer detection.